Conclusion
The simulated incidence of stroke/SE incidence and major bleeding might reflect the real-world event rate in AF patients. Even some differences existed in the absolute rates of stroke/SE and major bleeding between observed and simulated studies, the results confirmed similar effectiveness and safety to ROCKET AF comparing rivaroxaban and warfarin in AF patients.
Keywords :rivaroxaban; atrial fibrillation (AF); simulation; randomized controlled trial (RCT); observational study